Evidence map›Paper›PMID 38693188›Full record

ArticleScientific reports2024

Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.

Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Johannes Uhlig *Department of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany. Johannes.uhlig@med.uni-goettingen.de.
Annemarie Uhlig *Department of Urology, University Medical Center Goettingen, Göttingen, Germany.
Hari DeshpandeSmilow Cancer Hospital, New Haven, CT, USA.
Philipp StröbelDepartment of Pathology, University Medical Center Goettingen, Göttingen, Germany.
Lutz TrojanDepartment of Urology, University Medical Center Goettingen, Göttingen, Germany.
Joachim LotzDepartment of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany.
Michael HurwitzSmilow Cancer Hospital, New Haven, CT, USA.
Omeed HafezDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Peter HumphreyDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
Viktor GrünwaldClinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany.
Hyun S KimDepartment of Diagnostic Radiology and Nuclear Imaging, University of Maryland School of Medicine, Baltimore, MD, USA.
Smilow Cancer Hospital · USUniversity of Göttingen · DEUniversity of Maryland, Baltimore · USYale University · USEssen University Hospital · DEUniversity of California, Los Angeles · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

To assess epidemiology, clinical presentation, treatment and overall survival of adult patients with renal sarcomas, the 2004-2016 SEER and NCDB databases were queried for adult patients diagnosed with renal sarcoma, calculating average annual age-adjusted incidence rates (AAIR) and average annual percentage change (AAPC) as well as overall survival (OS). In n = 1279 included renal sarcoma patients, AAIR remained constant over the study period (average 0.53 cases/1million; AAPC = 0.7, p = 0.6). Leiomyosarcoma (AAIR 0.14 cases/1 million) and malignant rhabdoid tumors (0.06 cases/1 million) were most common. Sarcoma histiotypes demonstrated considerable heterogeneity regarding demographic and cancer-related variables. Patients presented with advanced local extent (T3 33.3%; T4 14.2%) or distant metastases (29.1%) and commonly underwent surgical resection (81.6%). Longer OS was independently associated with younger age, female sex, lower comorbidity index, low T stage, negative surgical margins, absence of tumor necrosis or distant metastases and leiomyosarcoma histiotype (multivariable p < 0.05 each). Treatment efficacy varied according to sarcoma histiotype (interaction p < 0.001). Accounting for 0.25% of renal malignancies, renal sarcomas include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy, thereby reflecting soft-tissue sarcoma behavior. Renal sarcoma treatment patterns follow recommendations by renal cancer guidelines with surgical resection as the cornerstone of therapy.

Indexed as

Kidney NeoplasmsSarcomaAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedSEER ProgramTreatment OutcomeEpidemiologyRenal cancerRenal sarcomaSurgerySurvival

Identifiers

PMID38693188
PMCPMC11063157
OpenAlexW4396597996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.